abbott laboratories posts
FeedPosted Mar 7th 2011 11:00AM by Steven Halpern (RSS feed)
Filed under: Abbott Laboratories (ABT), Lockheed Martin (LMT), Duke Energy (DUK), Norfolk Southern Corp. (NSC)
"I've put together a retirement blue print that will allow anyone who is 20 years old or younger to retire a multi-millionaire," says Steve Christ.
The editor of The Wealth Advisory explains, "This diversified portfolio, contains a transport, a utility, a tech company, a health care giant, and a defense contractor, all of which pay nice steady dividends with room for growth.
"All you need to start is $15,000 initial investment to go along with an additional $100 bucks a week in total contributions divided among the five stocks.
Continue reading A 'Fool-Proof' Retirement Plan for 20-Year-Olds
Posted Jan 28th 2011 10:00AM by Steven Halpern (RSS feed)
Filed under: Coca-Cola (KO), PepsiCo (PEP), Newsletters, AT and T (T), Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Altria Group (MO), Procter and Gamble (PG), United Technologies (UTX), S and P 500, DJIA, Stocks to Buy, Molson Coors Brewing Co. (TAP)

"High-quality stocks bought at historically low-price-to-high-yield offer the best potential for downside protection and upside appreciation," says dividend specialist
Kelley Wright.
The editor of
IQ Trends explains, "Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.
"Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years. Do we believe that all 10 will go up simultaneously or immediately? Of course not.
Continue reading The Timely 10: Best Blue Chip Dividend Buys
Posted Jul 14th 2010 1:20PM by Steven Halpern (RSS feed)
"Our primary purpose is to assist investors in growing their capital and income base from which to derive cash for their current and future needs," says blue chip stock specialist
Kelley Wright.
The editor of
Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.
"The Timely Ten list of stocks is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.
Continue reading Blue Chip Buys: The Timely Ten
Posted Mar 30th 2010 10:00AM by Mark Fightmaster (RSS feed)
Filed under: Abbott Laboratories (ABT)

AstraZeneca (
AZN) and Abbott Laboratories (
ABT) announced this morning they received a complete response letter from the Food and Drug Administration regarding their
new drug application for Certriad capsules. The FDA requested more information. The companies stated that they are currently evaluating the FDA's letter and will continue discussions with the agency to see what the next step will be with the drug. AZN and ABT will then respond to the FDA's request for further information.
Certriad is for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including the "bad" cholesterol (LDL), high triglycerides, and low "good" cholesterol (HDL). The active ingredients in Certirad are Crestor and Trilipix from ABT and AZN.
Continue reading AstraZeneca and Abbott Labs Receive FDA Response
Posted Mar 12th 2010 11:00AM by Laurie Pasternack (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Goldman Sachs Group (GS), Analyst Initiations, Gilead Sciences (GILD)
Analyst Upgrades
- Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
- JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
- Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
- Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
- Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
- Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.
Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...
Posted Dec 15th 2009 10:40AM by Mark Fightmaster (RSS feed)
Filed under: Deals, Abbott Laboratories (ABT)

Bright and early this morning, lab-technology innovator StarLIMS (
LIMS) announced that
it will be bought by pharmaceutical firm Abbott Laboratories (
ABT) for roughly $123 million. This purchase price reflects a per-share price tag of $14 for LIMS, which closed Monday's trading session near the $10 region.
Needless to say, LIMS was the subject of heavy pre-market trading, which pushed the per-share price closer to the premium paid by ABT. According to the report, ABT will acquire all outstanding equity of LIMS, which currently has roughly $18 million cash in hand.
Continue reading Abbott Labs wishes upon a StarLIMS
Posted Dec 9th 2009 1:30PM by Sheldon Liber (RSS feed)
Filed under: Management, Competitive Strategy, General Electric (GE), Berkshire Hathaway (BRK.A), Market Matters, Diageo plc (DEO), Abbott Laboratories (ABT), Options, Deere and Co (DE), Anadarko Petroleum (APC), Chasing Value™, Anglo American (AAUKY), Stocks to Buy, American Eagle Outfitters (AEO), EZCORP (EZPW), Brown Forman (BF.A)

Today it's time to do some trimming of the fourteen stocks and four options on the contenders list. This review will prioritize the companies by price-to-book (P/B), price-to-sales (P/S) and return-on-equity (ROE). This does not preclude more possible stocks being added and the final list will not be done until the end of the month.
We will also compare recent stock prices to three-year highs to give us a relative idea where the stock floated in rosier times.
Continue reading Chasing Value: Ten stocks for 2010 Part 8: Making some cuts
Posted Nov 23rd 2009 1:00PM by Sheldon Liber (RSS feed)
Filed under: Microsoft (MSFT), Abbott Laboratories (ABT), Chasing Value™, Stocks to Buy
The march toward year end continues as three more stocks are reviewed in a search for the eventual 2010 stock picks. This year there will be nine stocks with a new wrinkle, I will add one naked put.
These options have contributed to a mind-boggling return on my 2009 portfolio, exceeding 200% to date. This has been a very unusual year, and I bet against the rampant fear in the market. I will not pretend for a moment that this is repeatable. What I will do is share my opinions and investing adventure, hoping to stimulate investor interest and dialog.
Continue reading Chasing Value: Ten stocks for 2010 -- Part 5
Posted Jul 14th 2009 1:00PM by Sheldon Liber (RSS feed)
Filed under: Good news, Market Matters, Getting Started, Diageo plc (DEO), Abbott Laboratories (ABT), Automatic Data Proc (ADP), ConocoPhillips (COP), Duke Energy (DUK), Serious Money, Oil, Stocks to Buy, Financial Crisis

The market may be entering a more volatile period or it may just go sideways for a while. The last few weeks the market has been down. Maybe it is because the rapid rise mid-March through mid-June is forcing people to stop and take a breath, or perhaps it is because investors are having second thoughts about whether the "green shoots" Ben Bernanke spoke of in regards to a healing economy were really just weeds.
All in all, I still believe that there is opportunity in this market and I have been trying to point out how investors can get in with as little risk as possible, while being rewarded for their patience now, and when a recovery ensues ---- whenever that is. To this end, two weeks ago I posted
Serious Money: Five high-yield, safe, diversified stocks and decided to follow up with another five I think will produce similar results.
Continue reading Serious Money: Five more high yield, safe, diversified stocks -- Part 2
Posted Jun 25th 2009 11:00AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Abbott Laboratories (ABT), Teva Pharm Indus ADR (TEVA), S and P 500, DJIA, Stocks to Buy
"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.
"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.
"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.
Continue reading Tech talk from MarketWatch
Posted Apr 14th 2009 10:30AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Abbott Laboratories (ABT), Stocks to Buy
"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.
"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
"The company employs more than 68,000 people and markets its products in more than 130 countries.
"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.
Continue reading Abbott (ABT): An 'income machine'
Next Page >